Commercial, GHG Emissions - February 24, 2022
Fresenius Medical Care Commits to 2040 Climate Neutrality
Fresenius Medical Care announced Feb. 22 that it is committed to becoming climate neutral in its Scope 1 and 2 emissions by 2040.
The provider of products and services for renal disease care plans to also continuously assess its Scope 3 emissions across its value chain to identify ways to further reduce those emissions. In the interim, the company plans to reduce Scope 1 and 2 emissions by 50% by 2030, compared to 2020 levels, primarily through the transition to renewable electricity. By 2025, Fresenius Medical Care plans to source 100% renewable electricity for its United States and Canada operations and 80% for its operations in the European Union, mainly through VPPAs.
To further reduce its carbon footprint, the company will seek opportunities for energy efficiency investments, self-generation of renewable electricity and exploring new technologies that take into account the entire life cycle of their products. Fresenius will also purchase Energy Attribute Certificates for renewable power during the transition period to offset unavoidable emissions.
“We are at the beginning of our journey toward climate neutrality,” CEO Rice Powell said in a statement. “In the coming years, we will continuously examine additional ways to reduce emission levels and further expand our plans. Climate change is one of the greatest challenges of our time, and progress in protecting the climate can only be achieved through the cooperation of governments, industry and society. We want to play our part.”